Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axogen (AXGN) Cash & Equivalents (2016 - 2025)

Axogen (AXGN) has 16 years of Cash & Equivalents data on record, last reported at $35.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 29.01% year-over-year to $35.5 million; the TTM value through Dec 2025 reached $35.5 million, up 29.01%, while the annual FY2025 figure was $35.5 million, 29.01% up from the prior year.
  • Cash & Equivalents reached $35.5 million in Q4 2025 per AXGN's latest filing, up from $23.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $53.1 million in Q2 2021 and bottomed at $7.7 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $25.0 million, with a median of $21.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: tumbled 77.73% in 2022, then soared 117.17% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $32.8 million in 2021, then tumbled by 53.34% to $15.3 million in 2022, then surged by 102.98% to $31.0 million in 2023, then decreased by 11.18% to $27.6 million in 2024, then increased by 29.01% to $35.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $35.5 million in Q4 2025, $23.9 million in Q3 2025, and $20.0 million in Q2 2025.